Chemotherapy

What is Chemotherapy?

Chemotherapy is a group of toxic drugs that kill cells (mesothelioma, other cancers, and healthy cells) by damaging their DNA. Chemotherapy is a cytotoxic therapy, meaning it kills cells. Chemo drugs target rapidly growing cancer cells, but they can also affect healthy cells that grow rapidly such as blood cells. The effect of these drugs on both cancer and normal cells often causes chemo side effects.

Alimta (Pemetrexed) and Cisplatin

As of this writing, the only FDA approved chemotherapy for mesothelioma is a combination of Alimta (pemetrexed) and cisplatin. In February 2004, the Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma in combination with cisplatin for patients whose disease is either inoperable or who are not otherwise candidates for curative surgery. Patients who take this chemo regimen are often prescribed folic acid and vitamin B12 supplement to help reduce side effects from the chemotherpay. Patients are usually prescribed corticosteroids to reduce the risk of skin rashes as well.

The recommended dose of pemetrexed is 500 mg/m administered as an intravenous infusion over 10 minutes on day 1 of each 21-day cycle together with cisplatin at a dose of 75 mg/m infused over 2 hours beginning 30 minutes after the pemetrexed infusion.

The Clinical Trial that Approved Alimta (Pemetrexed) and Cisplatin

There was one key clinical trial that led to the FDA approval of this regimen for mesothelioma. Two hundred twenty-six pleural mesothelioma patients were randomized to receive pemetrexed and cisplatin, while 222 patients were randomized to receive cisplatin alone. The primary study end point was survival. Median survival times were 12.1 months for the pemetrexed plus cisplatin treatment group and 9.3 months for the cisplatin alone group.

Median time to progression (regrowth of tumor) was longer in the pemetrexed/cisplatin arm of the study, 5.7 months versus 3.9 months. This means that the mesothelioma patients who received both drugs had their tumors return a median of 1.8 months longer versus those who only got one drug.

Like most chemo drugs, pemetrexed kills blood cells so the most common adverse events were neutropenia, fatigue, leukopenia, nausea, dyspnea, and vomiting.

On February 4, 2004, pemetrexed was approved by the FDA in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is inoperable or who are otherwise not candidates for curative surgery.

Related Posts

Treatment for Pericardial Mesothelioma: Chemotherapy is Best - Some of the nation’s top cancer researchers say chemotherapy is the best treatment for pericardial mesothelioma.  Even surgery does not extend survival as well as chemotherapy. Doctors at the University of Texas reached that conclusion after studying more than 100 cases of pericardial mesothelioma. Surgery is still the most common treatment for pericardial mesothelioma. But the new research suggests that chemotherapy may be better. In the study, chemotherapy and cancer spread were the only factors that seemed to impact mesothelioma survival. What is Pericardial Mesothelioma? Malignant mesothelioma tumors grow on the linings around internal organs. The most common type is pleural mesothelioma which grows near the lungs. Peritoneal mesothelioma on the abdominal lining is the second most common type. Pericardial … Continue reading Treatment for Pericardial Mesothelioma: Chemotherapy is Best »

Chemotherapy for Mesothelioma May Work Better with TroVax - UK researchers say a cancer vaccine called Trovax has the potential to boost the power of chemotherapy for mesothelioma. Chemotherapy is the main treatment for malignant pleural mesothelioma. Mesothelioma is a cancer of the lung lining caused by asbestos exposure. It is very hard to treat. Even people who have chemotherapy for mesothelioma do not usually live more than two years after diagnosis. Mesothelioma researchers are always looking for ways to improve chemotherapy for mesothelioma. It is often combined with other treatments like surgery, radiation or immunotherapy. Now, scientists think adding TroVax to mesothelioma chemotherapy may be another good option. What is the TroVax Cancer Vaccine? The TroVax cancer vaccine is made by UK-based Oxford BioMedica. It contains an altered … Continue reading Chemotherapy for Mesothelioma May Work Better with TroVax »

Faster Mesothelioma Chemotherapy Deemed “Safe and Feasible” - Researchers in The Netherlands say it may be possible to deliver faster mesothelioma chemotherapy without doing any additional damage to the kidneys. If they are right, it could make mesothelioma treatment more accessible and convenient for patients. Most malignant mesothelioma patients will have chemotherapy. The most common type of chemotherapy is by infusion. Each session takes several hours. Every mesothelioma patient undergoing chemotherapy faces the possibility of kidney damage. That possibility can even limit how much medicine doctors can use. But a new Dutch study finds that faster mesothelioma chemotherapy may be as safe for the kidneys as standard chemotherapy. Analyzing Faster Mesothelioma Chemotherapy The study included 230 lung cancer patients who had chemotherapy. Some of the study subjects had … Continue reading Faster Mesothelioma Chemotherapy Deemed “Safe and Feasible” »

Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma - A sugar supplement might be able to slow the growth of mesothelioma and others types of cancer. The sugar supplement is called mannose. Mannose occurs naturally in some fruits, including cranberries. It is also sold as a nutritional supplement. Researchers with Cancer Research UK and Worldwide Cancer Research say mannose slowed the growth of tumors in mice. The test mice had leukemia, bone cancer, ovarian cancer, or bowel cancer. In a new report in the journal Nature, the researchers say mannose made mouse tumors smaller. It also helped chemotherapy work better and helped some mice live longer. How Does Mannose Slow Tumor Growth? All cells in the body need glucose to grow. This includes cancer cells. Cancers like mesothelioma need … Continue reading Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma »

Mesothelioma Surgery PD Comparison - Lung-sparing surgery is another name for pleurectomy/decortication (PD). In PD, surgeons take out as much mesothelioma cancer as they can without taking out one of the lungs. The other main type of mesothelioma surgery is called EPP (extrapleural pneumonectomy). In that surgery, doctors do take out a lung when they take out the mesothelioma tumor. Some studies say patients who have PD surgery live longer than people who have EPP. They may also have fewer problems after surgery. What is the New Clinical Trial? Researchers in Belgium and The Netherlands are running a test called EORTC 1205. EORTC 1205 is a clinical trial. Clinical trials test new drugs or treatments to see how well they work in people. Right now, … Continue reading Mesothelioma Surgery PD Comparison »

Study Predicts New Mesothelioma Therapies on the Horizon - A new article published by a pair of UK scientists predicts a brighter future for mesothelioma patients thanks to a growing understanding of the disease and how to treat it. Malignant mesothelioma is the cancer most closely associated with asbestos. Although only a small percentage of asbestos-exposed people go on to develop mesothelioma, those who do face a grim prognosis. Doctors learned early on that standard cancer treatments rarely work for patients with mesothelioma. But Anna Bibby and Nick Maskell with Bristol Medical School and the North Bristol Lung Centre say the large amount of high-quality mesothelioma research conducted in the last decade has moved medicine closer to finding a cure for this intractable cancer. Important Mesothelioma Research Findings In … Continue reading Study Predicts New Mesothelioma Therapies on the Horizon »

Mesothelioma Tumors Thrive in Low Oxygen Environment - South Korean researchers have uncovered a clue that might help explain why mesothelioma tumors are so aggressive — and what can be done to counter that aggression. The new study centers on hypoxia, a deficiency in the amount of oxygen reaching the tissues. It is a hallmark of many types of solid tumors and it turns out that malignant mesothelioma tumors are no exception. Patients with these hypoxic tumors tend to worsen quickly, be less responsive to treatment, and end up with poor outcomes. The Effect of Oxygen on Malignant Mesothelioma Scientists in the Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University are trying to better understand how hypoxia effects human malignant mesothelioma cells and exactly what … Continue reading Mesothelioma Tumors Thrive in Low Oxygen Environment »

Drug-Coated Film May Prevent Mesothelioma Recurrence - Mesothelioma researchers in Italy have developed a new surgical technique with the potential to dramatically increase the odds of surviving malignant pleural mesothelioma. Pleural mesothelioma is a rare and aggressive cancer that grows on the membranous tissue (pleura) surrounding the lungs. It is most common in people who have ever lived or worked in the presence of deadly asbestos dust.                       The new technique involves placing a drug-coated polymer film directly on the mesothelial surface after tumor-removal surgery as a way to prevent recurrent pleural mesothelioma. In a new article in the European Journal of Pharmaceutical Science, researchers at the University of Parma say the film “almost completely prevented tumor recurrence” in treated mice. Battling Recurrent Mesothelioma The typical treatment … Continue reading Drug-Coated Film May Prevent Mesothelioma Recurrence »

Compound Makes Mesothelioma Tumors More Susceptible to Chemo - Swiss cancer researchers may have found a way to get around malignant mesothelioma’s notorious resistance to chemotherapy with an investigational metal-based compound called RAPTA-T. Malignant pleural mesothelioma is an incurable and highly aggressive cancer. One of the reasons it is so deadly is that it rarely responds to standard cancer treatments. Even the treatment combination that is considered the standard of care for pleural mesothelioma—pemetrexed (Alimta) and cisplatin—is only effective in about 4 out of 10 patients. But scientists with Centre Hospitalier Universitaire Vaudois and the Swiss Federal Institute of Technology in Lausanne, Switzerland have discovered a counterintuitive way to ramp up the cancer-killing power of mesothelioma chemotherapy. Creating a “Healthier” Tumor The element on which the RAPTA-T compound is … Continue reading Compound Makes Mesothelioma Tumors More Susceptible to Chemo »

Immunotherapy Drug Produces ‘Exceptional and Sustained Response’ in Mesothelioma Patient - As part of what they call the “new era” of mesothelioma immunotherapy research, doctors in Ohio and Florida have just published the case report of a man whose pleural mesothelioma was stopped in its tracks with the drug nivolumab. The case is detailed in the latest issue of the American Journal of Case Reports by researchers at the University of Florida and The Christ Hospital in Cincinnati. Details of the Mesothelioma Case Report The patient in question had been diagnosed with malignant pleural mesothelioma, a deadly cancer that typically carries a poor prognosis, even with aggressive treatment. In fact, even though chemotherapy with a combination of cisplatin and pemetrexed (Alimta) is considered the standard-of-care for malignant mesothelioma, fewer than 4 … Continue reading Immunotherapy Drug Produces ‘Exceptional and Sustained Response’ in Mesothelioma Patient »